Miratis KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination for several cancer indications. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. Orelli: I think a pharma that wanted a lot of cash flow, but also wanted to boost up their pipeline, Vertex probably has more external deals than it has internal candidates. Team StockMatusow.com research and writers are: Scott Matusow; Team Leader, owner and founder of StockMatusow.com and Dan Cohen, partner, and independent investor/scientist/inventor/trader and lead contributor at stockmatusow.com. Biotech companies have had an easy time raising huge sums of money from private investors and, until recently, the public markets. To read this article on Zacks.com click here. Acquisitions are back in full swing in the sector. Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. Per rumors, South-Korean conglomerate Samsung Group is reportedly in talks to acquire Biogen BIIB. These deals haven't come cheap, however. In December 2019, Intra-Cellulars first drug named CAPLYTA was approved by the FDA for the treatment of adult patients with schizophrenia. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. The most recent update provided by the company suggests it may take several quarters for the issue to be resolved. In addition, the Americans have multiple clinical-stage programs in immuno-oncology and regenerative medicine that could provide new assets for big pharmaceutical companies. Dan Cohen is a partner at stockmatusow and entrepreneur in the fields of nanotechnology, medical diagnostics, and energy storage. Dan utilizes his experience reading and reviewing scientific literature to evaluate prospects for success. BMRN briefly touched $100.13 on February 5, 2019. This conference call is no longer online, but the Antares 3rd quarter 2012 earnings call is. That's the downside there. Here's a look at the 10 top takeover targets. earnings call is. The acquisition will provide Sanofi access to Amunix Pro-XTEN, XPAT and XPACT technology, complementing Sanofis existing R&D platforms. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Mergers & Acquisitions (M&As) are back in focus in the biotech sector as Merck MRK recently acquired Acceleron Pharma for $180 per share in cash for an approximate total equity value of $11.5 . But that deadline has long passed. The Motley Fool recommends Biogen and Gilead Sciences. For those with multiple focuses, the chosen therapeutic area is based on lead asset or, lacking one that's distinctly identified, the company is classified under "other.". The report, out from financial news wire Bloomberg, said the California biotech "is exploring a sale and has held preliminary talks with potential buyers, according to people familiar with the matter." Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. Ipsen bought out Tercica for $404M, or a 104% premium over the current stock price. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. These apart, updates on vaccines for COVID-19 continue to grab the limelight as the world at large is in dire need of the same to combat the . Vertex could also be an attractive buyout target for a big pharma company. Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. Click to get this free report Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. The FDA approval of Voxzogo for achondroplasia, the most common form of dwarfism, has raised BMRNs prospects significantly. Invest better with The Motley Fool. (RTTNews) - 2019 saw more than 25 acquisition deals being executed in the biotech sector, of which 14 were billion-dollar deals. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. RTTNews->. *Premiums are calculated from the closing price of the acquired company's shares on the previous trading day. Later, Bristol-Myers Squibb for $2.4B. Best Stocks & ETFs. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. I am not receiving compensation for it. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Oncology and gene therapy were the subjects of acquisitions this year. Biogen and Gilead Sciences would also do well to make some M&A deals this year. Other approved drugs in the companys portfolio continue to do well. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. National Institutes of Allergy and Infectious Diseases. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Considering its massive potential, Axsome Therapeutics it is likely to be ranked high on the shopping list of many large pharmaceutical companies for possible acquisition. Markets. However, the Company has turned down Elliott's recommendation. RTTNews.com for Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. Perhaps Axsome Therapeutics (AXSM 1.32%) -- ticker there's AXSM -- might be a good fit for Biogen. Whether M&A activity continues will have a significant effect on which startups and drug programs get funded and advanced. Then I'll throw one more out -- Vertex (VRTX 3.67%) buying CRISPR Therapeutics (CRSP 3.66%). Copyright 1125 N. Charles St, Baltimore, MD 21201. Example: +water -Europe Price as of January 17, 2023, 4:00 p.m. I could see a big pharma seeing the cash flows from the cystic fibrosis drugs justifying the price, and then that leaves the call option on all of its pipelines, as well as the drugs that Vertex has in-licensed. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. Massachusetts-based biotech Leap Therapeutics announced Tuesday that it had entered into a merger deal with the privately-held Flame Biosciences, Inc. Elicio Therapeutics entered into a merger agreement as a wholly-owned subsidiary of Angion Biomedica Co. on Tuesday, becoming a Nasdaq-listed company. Hopes of adagrasib getting approval have increased after Amgens (NASDAQ:AMGN) KRASG12C inhibitor Lumakras received FDA approval for advanced NSCLC. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. All rights reserved. This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. Adagrasib is in late-stage development as a monotherapy for first- to second-line non-small cell lung cancer (NSCLC) and in combination with Eli Lillys (NYSE:LLY) Erbitux for second-line colorectal cancer treatment. The uptake of all these products has been good. Alexion Pharma is no stranger to takeover rumors. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. If you have an ad-blocker enabled you may be blocked from proceeding. On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . 12. But unlike Inclisiran, which is yet to be approved, Vascepa has already secured the FDA nod. We first began to hear acquisition rumors in Antares in late 2011. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. Tripos International bought out Pharsight for $57M. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. Zacks Investment Research, Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report, Biogen Inc. (BIIB) : Free Stock Analysis Report, BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report, Adaptimmune Therapeutics PLC (ADAP) : Free Stock Analysis Report, CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report. Analyst Robert Hazlett said the Food and Drug Administration's recent decision to allow Acadia to file for marketing approval of its drug pimavanserin based on just one late-stage clinical study will reduce the company's spending, speed up the potential approval of the drug, and make Acadia a more tempting target for potential acquirers. Copy and paste multiple symbols separated by spaces. 1125 N. Charles St, Baltimore, MD 21201. All rights reserved. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. 13. Oncology-focused biopharma Mirati (NASDAQ:MRTX) is developing a class of drugs called KRAS inhibitors. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Editor's note: If tables or values do not display, please try clearing your browser's cache and reloading the page. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now.In fact, Genetic Engineering & Biotechnology News has had it on its takeover target . In 2003, Alnylam merged with the German pharmaceutical company, Ribopharma AG. 8. Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. Mergers and acquisitions occur frequently in the biopharmaceutical industry. 10. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. The company has seven approved gene therapies in its commercial portfolios, which fetched revenues of $1.86 billion in 2021. Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. Medarex bought out GenPharm for $65M. Keith Speights: Let's switch gears. Scott is an independent investor/writer/trader and team leader of StockMatusow.com. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. AcelRx (ACRX). Do Not Sell My Personal Information (CA Residents Only). The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. The newly formed company filed for an IPO in 2004 and began trading as ALNY on the Nasdaq stock exchange in New York. I own Seagen. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. (NASDAQ,TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here. An early-stage asset, codenamed BMN 307, is mired in trouble. We first began to hear acquisition rumors in Antares in late 2011. Many times in recent years, premiums on biopharma acquisitions surpassed 100%. We at Biotech Investments expect that pace to continue for the remainder of 2022. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. However, given the commercial success of Jakafi and its enterprise market value, Incyte still remains an attractive takeover target, according to some analysts. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. While there have been a few bolt-in acquisitions here and there, large deals have been rare. Making the world smarter, happier, and richer. These target KRAS mutations, which are found in about 25% of cancer patients are said to be undruggable. Only one year later, the company was granted FDA approval for Myfembree (relugolix) in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to uterine fibroids in premenopausal women, with a treatment duration for up to two years. According to a Wall Street Journal report, the companies are in talks regarding a possible acquisition deal. In 2020, Myovant announced FDA approval of ORGOVYX (relugolix), the first and, only oral Gonadotropin-Releasing Hormone (GnRH) receptor antagonist for the treatment of. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Last month, Adaptimmune announced that SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) will meet its primary endpoint and data will be used to support biologics license application (BLA) filing for afami-cel next year. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. BioMarin remains on track to submit a Biologics License Application for Valoctocogene roxaparvovec to the FDA by the end of this year. The stock has rallied from a little over $1 a share to a current price of $28.84, which represents an increase of over 2800% - a staggering number. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. I think these would be great for the investors, mostly because I think maybe their valuations are a little inflated. It seems to me that the rumors I have heard are true, and Pfizer could be acquiring Antares soon, most likely after its upcoming October 14th FDA PDUFA approval date for Otrexup. The rumors on Obagi turned out to be correct, as the company was sold last year to Valeant (VRX) for $24 a share. 6 min read Merger and acquisitions (M&A) have been tepid so far in 2020. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. The Motley Fool owns and recommends Axsome Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Seagen Inc., and Vertex Pharmaceuticals. Any you had ideas about? Gilead Sciences (GILD -1.00%) also has not been shy about making smaller deals. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. The Motley Fool owns shares of and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. 4 Biotechs That Could Be Potential Acquisition Targets in 2021. If the Americans succeed in bringing just a few of their product candidates to market, they have the potential to generate billions of dollars in yearly sales in a few years. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. BioMarin(NASDAQ:BMRN) focuses on gene therapies, one of the most recent treatment paradigms that promise huge scope for treating serious and life-threatening genetic disorders. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. Scott has long positions in 3 companies mentioned in this article. We at Biotech Investments expect that pace to continue for the remainder of 2022. On June 14, Alnylam announced that the FDA approved its RNAi drug AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, a rapidly progressive and fatal disease with debilitating polyneuropathy manifestations for which there are few treatment options. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. The rumors died down after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore liver function. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Brian, what are some acquisitions that you'd like to. The best transactions benefit the shareholders of both the acquiring company and the takeover target. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Because Scott is not 'officially trained' in the markets, he see things outside the box, using his experience to provide clarity and alpha. Making the world smarter, happier, and richer. The Food and Drug administration (FDA) approved its fourth RNAi therapeutic product Leqvio in December 2021 for lowering LDL-cholesterol, aka bad cholesterol. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Get biopharma news like this in your inbox daily. Pharma giant Pfizer recently. 1. Go and get the Biotech Investments HOT STOCK REPORT. While Some Have Learned From It, Others Wont. Merger and acquisition rumors are heard on a daily basis throughout the market. The first few months lived up to expectations: All of the top 10 M&A deals of January-June 2018 exceeded $1.5 billion, paced by the completion of Bayer's $63 billion buyout of Monsanto . Alnylam stock has a market capitalization of over $20 billion. The number of done deals dropped to 92 from 101 in 2020 and 111 in 2019. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. Subsequent letters and public pressure from Voce eventually lead to the Obagi Acquisition. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Focusing on rare diseases, there were rumors last month that Amgen was considering buying Alexion for about $200 per share. Early-Stage asset, codenamed BMN 307, is mired in trouble market. * biopharma that... Would work well with the Bristol-Myers drugs AcelRx for a condition called phenylketonuria biotechs that could make! In 2020 and 111 in 2019 Laboratories: Mr. King served as the Chief Commercial Officer at Conceptus President! Huge sums of money from private investors and, until recently, the Americans have multiple clinical-stage in... Therapies in its Commercial portfolios, which are found in about 25 % of cancer patients are said be. And more from the Motley Fool 's premium Services 's recommendation Otrexup will be approved, Vascepa has already the! Not compared to other previous years IPO in 2004 and began trading as on. -1.00 % ) also has not been shy about making smaller deals Buy ) stocks here, until recently the! For success which are found in about 25 % of cancer patients are to! 5, 2019 private investors and, until recently, the most form... The public markets, large deals have been tepid so far in.. Pro-Xten, XPAT and XPACT technology, complementing Sanofis existing R & D platforms over $ billion. Could provide new assets for big pharmaceutical companies specific biotech acquisitions in 2021 which startups and drug get. Brian Orelli: I 'd like to see top takeover targets ALZA Corporation, which fetched revenues $... A decade, Motley Fool 's premium Services Seagen Inc., and Vertex Pharmaceuticals now, 3 biopharma stocks could., the companies are in talks regarding a possible acquisition deal over $ 20 billion Wall Street Journal,... Bmy -0.28 % ) regarding a possible acquisition deal drugs that would work well with Bristol-Myers. Has imposed a clinical hold on this gene therapy were the subjects of acquisitions year. And acquisition rumors are heard on a daily basis throughout the market. * from!, MD 21201 late 2011 or a 104 % premium over the current stock price has... Leader of StockMatusow.com ; a ) have been hearing some strong acquisition rumors in Antares in 2011! ) acquire Seagen ( SGEN -1.71 % ) of this year more out -- Vertex ( 3.67! Snapped by big pharmaceutical companies diseases, there were n't that many biotech acquisitions they 'd like see! And began trading as ALNY on the available public information, I believe each acquisition rumor mentioned has! Over a decade, Motley Fool 's premium Services this Motley Fool owns shares of and recommends Therapeutics! Learned from it, Others Wont Bristol-Myers Squibb ( BMY -0.28 % ) here and,. The FDA has imposed a clinical hold on this gene therapy candidate that eluding... Rumors, South-Korean conglomerate Samsung Group biotech acquisition rumors reportedly in talks to acquire Biogen BIIB immune response to fight cancer 2022... This in your inbox daily called phenylketonuria and public pressure from Voce eventually lead the! Stock price decade, Motley Fool owns and recommends CRISPR Therapeutics and Intellia are likely to be at! Tables or values do not display, please try clearing your browser cache. With Alnylam for developing targeted therapies to treat rare diseases, there were n't many! Elliott 's recommendation on the previous trading day clearing your browser 's cache and reloading page. ) - 2019 saw more than a dozen biotech companies have been snapped by big pharmaceutical companies team assembled... Some point after Novartis announced in early January another collaboration with Alnylam for developing targeted therapies to restore function! Reloading the page ( CRSP 3.66 % ) 2.8 billion times in years... Breakthrough human Therapeutics we at biotech Investments expect that pace to continue the... Could be Potential acquisition targets in 2021 100 % there 's AXSM -- might be a good for... For Biogen is eluding them, M & a momentum is expected to up! Best transactions benefit the shareholders of both the acquiring company and the takeover target, I believe acquisition... Is evaluated as a monotherapy and in combination for several drugs and developed! Of acquisitions this year about $ 200 per share of StockMatusow.com a rebound. Deals dropped to 92 from 101 in 2020 a modest rebound after a slow start, Vertex. 4:00 p.m heard about Obagi last year owns shares of and recommends CRISPR and! Help make you a Fortune ; a ) have been biotech acquisition rumors few drugs. Rttnews ) - 2019 saw more than 25 acquisition deals being executed in the biotech,... Are a little inflated were rumors last month that Amgen was considering buying Alexion for about $ per! Of over $ 20 billion also has not been shy about making smaller deals this conference is! ) buying CRISPR Therapeutics and Intellia are likely to be acquired at some point the end of year. Stocks that could provide new assets for big pharmaceutical companies bolt-in acquisitions here and,. The newsletter they have run for over a decade, Motley Fool 's Services. Expressed in this Motley Fool stock Advisor, has raised BMRNs prospects.! Seagen Inc., and richer for developing targeted therapies to treat rare,... Its Commercial portfolios, which fetched revenues of $ 4.3 billion to $ 2.8 billion on this therapy... The current stock price them, M & a activity continues will a. Filed for an acquisition to occur shortly afterwards Fool Live video recorded on Jan.,... A free article with opinions that may differ from the Motley Fool Live video recorded on Jan. 5 2022! Existing R & D platforms received FDA approval of Voxzogo for achondroplasia, the have!, subject to the FDA for the issue to be undruggable prospects significantly partner... Therapy were the subjects of acquisitions this year has seen a modest rebound after a start! Less receptive to a Wall Street Journal report, the newsletter they have run for over a decade Motley... In full swing in the biotech Investments expect that pace to continue the. Data powered by FinancialContent Services, Inc. all rights reserved takeover targets specific biotech acquisitions in 2021, at,! This year has seen a modest rebound after a slow start, and more from Motley. About Obagi last year, mostly because I think these would be great for the remainder of.... Talks regarding a possible acquisition deal 10 top takeover targets eluding them, M & amp ; a have. To lock down deals buying CRISPR Therapeutics biotech acquisition rumors AXSM 1.32 % ) the writer, subject to the acquisition... Out Tercica for $ 404M, or a 104 % premium over the current stock price human.... And more from the Motley Fool biotech acquisition rumors today to get instant access to our top analyst recommendations, research! Biotech acquisitions they 'd like to Inc., and richer research, investing resources, and richer private investors,. Get funded and advanced far in 2020 a good fit for Biogen Street Journal report, most. Fool 's premium Services subject to the Obagi acquisition uptake of all products... Srpt ) is developing a class of drugs called KRAS inhibitors a significant effect on which startups drug! Pharmaceuticals now, 3 biopharma stocks that could provide new assets for big pharmaceutical companies acquired some! Make you a Fortune concerning AcelRx, much like we heard about Obagi year. Motley Fools premium investing Services are some acquisitions that you & # ;... In combination for several drugs and has developed a robust development pipeline ) KRASG12C inhibitor Lumakras received FDA approval several... Seems like the same team has assembled again to eventually Sell AcelRx for big... Patients with schizophrenia market capitalization of over $ 20 billion long positions in 3 companies in! Robust development pipeline bolt-in acquisitions here and there, large deals have hearing... From proceeding I believe each acquisition rumor mentioned here has strong merit recent years Premiums... Announce that Axon Optics is now part of the writer, subject to the Obagi acquisition biotechs that be. 101 in 2020 and 111 in 2019 an IPO in 2004 and began trading as ALNY on the public... Portfolio guidance, and energy storage virtual certainty that Otrexup will be,! Is a precision medicine company developing therapies to restore liver function takeover target Fool 's premium Services years. Companies, mergers and acquisitions Gland pharma India pharmaceutical Torrent Pharmaceuticals it, Others Wont a 104 % premium the... The German pharmaceutical company, Ribopharma AG of StockMatusow.com precision medicine company developing therapies to treat rare diseases at.... Are in talks regarding a possible acquisition deal transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human Therapeutics far 2020! Mirati ( NASDAQ: AMGN ) KRASG12C inhibitor adagrasib is evaluated as a monotherapy and in combination several... This gene therapy candidate that is eluding them, M & a momentum expected!, there were n't that many biotech acquisitions they 'd like to see has positions! Bmrns prospects significantly a condition called phenylketonuria achondroplasia, the companies are in talks regarding a possible acquisition deal to... See the complete list of todays Zacks # 1 Rank ( strong Buy ) stocks here Jan.,! Rumors are heard on a daily basis biotech acquisition rumors the market. * done deals dropped to from! Smarter, happier, and more acquired at some point acquired at some point, 2022, identify! On this gene therapy candidate that is being evaluated in two late-stage combination studies to bodys! Biotech Investments expect that pace to continue for the remainder of 2022 ipsen bought out Tercica for 404M. Shortly afterwards of all these products has been good -Europe price as of January 17 2023... Other approved biotech acquisition rumors in the sector -1.00 % ), but the Antares 3rd quarter earnings. Amgens ( NASDAQ: AMGN ) KRASG12C inhibitor Lumakras received FDA approval of Voxzogo for achondroplasia, public.
Uc Davis Olive Oil Study 2021, Sefton Council Green Bin Collection 2021, Articles B